Home >> Professional Blog

Comparative Effectiveness Study Exhibiting Superior Outcomes Of MiMedx EpiFix® Receives Award At SAWC Conference

MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced that one oral abstract and four poster abstracts showing the Company's EpiFix® allografts to be clinically superior and cost effective in the healing of chronic diabetic lower extremity ulcerated wounds, venous leg ulcers, diabetic foot ulcers, and burn injuries will be presented at the 2015 Symposium on Advanced Wound Care and Wound Healing Society (SAWC Spring/WHS) meeting, the leading national wound healing conference now in its 28th year.

The poster abstract chronicling the first ever multi-center randomized comparative effectiveness study showing superiority in examining side by side the performance, outcomes, wastage and cost of EpiFix as compared to Apligraf® or standard of care as a treatment for chronic lower extremity diabetic ulcers will be the recipient of an SAWC award. "We are pleased that this ground breaking study was selected as 3rd place Overall in the category of Clinical Research," said Parker H. "Pete" Petit, CEO of MiMedx.

The study article, authored by Charles M. Zelen, DPM FACFAS; Lisa Gould, MD PhD; Thomas E. Serena, MD FACS; Marissa J. Carter, PhD MA; Jennifer Keller, DPM; and William W. Li, MD, showed that MiMedx's EpiFix is superior to Apligraf® (the comparative bioengineered skin substitute) in both the rate of wound healing and the speed at which wounds are completely healed. Not only did EpiFix achieve superior clinical results, but the study also clearly demonstrated the dramatic cost savings of EpiFix over Apligraf. This study confirmed the wastage and excessive expense that are caused when size appropriate grafts are not made available to the practicing physicians.

MiMedx, the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, will also sponsor a Breakfast Symposium entitled "The Dynamic Impact of EpiFix, A Bioactive Tissue Matrix for the Treatment of Chronic Wounds." With physicians and study authors Charles Zelen, DPM; Thomas Serena, MD; Steve Bergquist, MD; and Matthew Garoufalis, MD, serving as moderators, the program will detail the healing properties and superb clinical outcomes of EpiFix.

Bill Taylor, President and COO of MiMedx, said, "We are honored to have our dHACM allografts and our proprietary PURION® Process highlighted in oral and poster presentations as well as EpiFix break-out symposia during the prestigious SAWC Spring/WHS meeting. It is always gratifying when independent clinical research and peer reviewed publications demonstrate the clinical and cost effectiveness of our allografts."

Read the entire news release